ArticleThe Journal of urology2012
Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy.
Article in The Journal of urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- The role of focal therapy in the management of localised prostate cancer: a systematic review.European urology · 2014Pooled it
- A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.Prostate cancer and prostatic diseases · 2016Trial
- Oncological outcomes post focal low-dose-rate brachytherapy in low-intermediate risk prostate cancer.BJUI compass · 2026Article
- Review
- A prospective comparison of implant quality between suture-coated seeds and uncoated seeds in prostate cancer brachytherapy.Journal of contemporary brachytherapy · 2024Article
- Review of brachytherapy clinical trials: a cross-sectional analysis of ClinicalTrials.gov.Radiation oncology (London, England) · 2024Review
- Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study.Journal of cancer research and clinical oncology · 2023Article
- Data-driven adaptive needle insertion assist for transperineal prostate interventions.Physics in medicine and biology · 2023Article
- Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning.Frontiers in oncology · 2021Article
- Voxel-based comparison of [EJNMMI research · 2020Article
- Targeting the cancer lesion, not the whole prostate.Translational andrology and urology · 2020Review
- Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.Prostate cancer and prostatic diseases · 2020Review
- Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer.International journal of urology : official journal of the Japanese Urological Association · 2020Article
- Individual lymph nodes: "See it and Zap it".Clinical and translational radiation oncology · 2019Article
- Improved specificity withEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Article
- Focal therapy for localized prostate cancer: is there a "middle ground" between active surveillance and definitive treatment?Asian journal of andrology · 2018Article
- Low dose rate prostate brachytherapy.Translational andrology and urology · 2018Review
- The prostate cancer focal therapy.Gland surgery · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
purposeWe report updated results of magnetic resonance imaging guided partial prostate brachytherapy and propose a definition of biochemical failure following focal therapy. MATERIALS AND
methodsFrom 1997 to 2007, 318 men with cT1c, prostate specific antigen less than 15 ng/ml, Gleason 3 + 4 or less prostate cancer received magnetic resonance imaging guided brachytherapy in which only the peripheral zone was targeted. To exclude benign prostate specific antigen increases due to prostatic hyperplasia, we investigated the usefulness of defining prostate specific antigen failure as nadir +2 with prostate specific antigen velocity greater than 0.75 ng/ml per year. Cox regression was used to determine the factors associated with prostate specific antigen failure.
resultsMedian followup was 5.1 years (maximum 12.1). While 36 patients met the nadir +2 criteria, 16 of 17 biopsy proven local recurrences were among the 26 men who also had a prostate specific antigen velocity greater than 0.75 ng/ml per year (16 of 26 vs 1 of 10, p = 0.008). Using the nadir +2 definition, prostate specific antigen failure-free survival for low risk cases at 5 and 8 years was 95.1% (91.0-97.3) and 80.4% (70.7-87.1), respectively. This rate improved to 95.6% (91.6-97.7) and 90.0% (82.6-94.3) using nadir +2 with prostate specific antigen velocity greater than 0.75 ng/ml per year. For intermediate risk cases survival was 73.0% (55.0-84.8) at 5 years and 66.4% (44.8-81.1) at 8 years (the same values as using nadir +2 with prostate specific antigen velocity greater than 0.75 ng/ml per year).
conclusionsRequiring a prostate specific antigen velocity greater than 0.75 ng/ml per year in addition to nadir +2 appears to better predict clinical failure after therapies that target less than the whole gland. Further followup will determine whether magnetic resonance imaging guided brachytherapy targeting the peripheral zone produces comparable cancer control to whole gland treatment in men with low risk disease. However, at this time it does not appear adequate for men with even favorable intermediate risk disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.